ACS Chemical Neuroscience Molecule Spotlight on Suvorexant
Author:
- 19 September 2012
- journal article
- review article
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 3 (9) , 647-648
Abstract
Suvorexant is a dual orexin antagonist currently in Phase III clinical trials for the modulation of sleep and is being developed by Merck. Recent Phase III results showed that patients taking the drug fell asleep faster and slept longer than those on placebo.Keywords
This publication has 5 references indexed in Scilit:
- Insomnia and the Performance of US Workers: Results from the America Insomnia SurveySLEEP, 2011
- The First Large-Scale Synthesis of MK-4305: A Dual Orexin Receptor Antagonist for the Treatment of Sleep DisorderOrganic Process Research & Development, 2011
- Discovery of the Dual Orexin Receptor Antagonist [(7R)-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the Treatment of InsomniaJournal of Medicinal Chemistry, 2010
- Prevalence, associated risks, and treatment patterns of insomnia.2005
- The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activityProceedings of the National Academy of Sciences, 1998